SABCS 2021

Good data with further questions for future treatment in a neoadjuvant setting

Solved and unsolved controversies of early breast cancer

Hypothesis-generating study in the HER2-enriched subtype

Metformin is not an anti-cancer drug

The next standard for TNBC?!

Critical consideration of the study data is necessary

Negative results with hope for translational projects

Re-evaluation confirms old data

The risk-adapted decision for or against AI has to be redefined

Benefit only related to chemotherapy?!

Metformin shows no efficacy for most cancer patients

Leading the way for other ct-DNA trials

Molecular-guided treatment is of value in combination with other therapeutics

Genomic signatures of DCIS

"Signatures Genomiche " nel carcinoma duttale in situ

Genomisch gesteuererte Therapie sinnvoll in Kombi mit weiteren Therapeutika

Hypothesen-generierende Studie beim HER2-enriched Subtyp

Negative Ergebnisse, aber Hoffnung für translationale Projekte

La metformina non può essere considerata un farmaco antitumorale

Kritische Betrachtung der Studiendaten notwendig

Erneute Auswertung bestätigt alte Daten

Muss die risiko-adaptierte Entscheidungsfindung bei AI überdacht werden?

E’ solo effetto della chemioterapia?

KEYNOTE-522 confirms ICI benefit in the neoadjuvant setting; what about toxicity?

RxPONDER: Benefit only for pre-menopausal patients? OFS/AI > CT? OFS leading to OS benefit?

cTRAK TN: ctDNA monitoring not yet ready for primetime. Lots of questions, very few answers!

HER2+ EBC: Chemotherapy free regimens? Extended adjuvant therapy? T-Dxd? Duuration of trastuzumab? What about HER2 low?

TNBC EBC: What is the new neoadjuvant standard treatment? The role of TILS, TMB, further predictive markers for ICI (gene expression signatures, CD8 infiltartion pattern, intrinsic subtypes, ctDNA) and PARP (HRD, sBRCA+, gPALB2+)

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of relapse or stratification of post-neoadjuvant treatment, new trials in premenopausal patients, NGS in early disease

HR+ EBC: What about PALLAS/PENELOPE-B? What is the difference to monarchE (Follow Up, Duraction, Administration, the drug itself)? PARPi vs. cdk4/6i?

Activity of T-Dxd across all Her2-expressing breast cancers

PFS improvement with fulvestrant in patients with emerging ESR1 mutation

Chekpoint inhibition in breast cancer

Elacestrant - less than we expected

Switching with molecular progress improves PFS

Reconfirming effect of T-DXd in patients with brain metastasis

Dato-Dxd for metastatic TNBC

Samuraciclib - new targeted therapy for luminal breast cancer?

Immuntherapy for high tumor mutation burden in metastatic breast cancer patients

IO + IO without resounding success in the mBC setting

Dato-DXd new promising ADC

Effectiveness depending on PDL1 status

T-Dxd is also active in patients with brain metastasis

TDXd is very efficient in patients with brain metastasis

Oral SERDs for early setting and adjuvant therapy

Pooled analyses shows OS benefit for most subgroups

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Pioneering study of personalized medicine in advanced breast cancer

My highlights of 2021 in metastatic breast cancer

Amazing period for patients with refractory metastatic TNBC

Promising results for TNBC patients

Very good news for endocrine resistant metastatic patients

3 updates - 3 new standards of care

Final results of the CPS score subgroup analyses show the optimal cutoff for mTNBC

Exciting novel therapies for metastatic TNBC

Best of the year: systemic therapy

Robust benefit of pembroluzimab in addition to chemotherapy

Imaging with mass cytometry can provide predictive information for therapy with immune checkpoint inhibitors

TROP2 - new target for improved chemotherapy

Precision oncology is beneficial in certain mBC patients

Which patients will benefit from Pembro in metastatic TNBC?

More good news for TDXd

Oral SERDs are efficient, but show high progression rate

Best of the Year: Systemtherapie

Important benefice de l’ajout du pembrolizumab à la chimiothérapie

Neues Target für optimierte Chemotherapie

L’imaging mass cytometry può aiutare a predire l’efficacia dell’immunoterapia

Elacestrant – poniżej oczekiwań

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Amélioration de la survie sans progression par le switch fulvestrant en cas d’apparition mutation ESR1 sous inhibiteurs aromatase

Checkpoint-Inhibition beim Mammakarzinom

Umstellung bei molekularem Progress verlängert PFS

Samuracyklib – nowe leczenie celowane w rakach luminalnych?

Activité du T-DXd dans les metastases cérébrales

Präzisionsonkologie funktioniert beim mBC

IO + IO ohne durchschlagenden Erfolg beim mBC

Dato-DXd – nowy obiecujący koniugat przeciwciała i cytostatyku

Wirksamkeit in Abhängigkeit von PDL1-Stautus

T-Dxd aktywny również w przerzutach do mózgu

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Werden orale SERDs die Therapie mit Fulvestrant in Zukunft ablösen?

Gepoolte Analyse zeigt OS Vorteil für fast alle Subgruppe

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil durch CDK4/6i

Wegweisende Daten für die personalisierte Medizin beim fortgeschrittenen Mammakarzinom

Mi retrospectiva del cáncer de mama metastático en 2021

Resultados finales de los análisis de los subgrupos de puntuación CPS demuestran el umbral ideal para pacientes de cáncer de mama triple negativo metastásico.

È un grande momento per i pazienti con tumore mammario metastatico triplo-negativo

Risultati promettenti nel tumore al seno triplo negativo

Résultats prometteurs dans le cancer du sein triple négatif

Buone notizie per i tumori mammari endocrino resistenti

MBC HER2+: How can we manage the metastatic disease and how can we improve therapy by de-escalating treatment in the metastatic setting?

MBC TNBC: Molecular tumor characteristics define the efficacy of new treatments - how do we implement new treatments in clinical practice?

MBC HR+: What is the best option after a CDK4/6i therapy?

Integrating patients perspectives in metastatic breast cancer

Targeting rare mutations in breast cancer - is this the way to go?

Are SERDs a future therapy for endocrine resistant metastatic patients?!

Treatment options for patients with metastatic TNBC

Therapy of brain metastasis – can T-DXd be the new SoC?

New ADCs on the horizon for TNBC patients